Dayvigo Is Exclusively for Nighttime Sleep
Yes, Dayvigo (lemborexant) is exclusively intended for nighttime use only—it must be taken right before going to bed when you can remain in bed for at least 7 hours before needing to be active again 1.
FDA-Approved Administration Requirements
The FDA labeling is explicit and unambiguous about timing:
- Take DAYVIGO only when preparing for or getting into bed
- Only take if you can stay in bed for a full night (at least 7 hours) before being active again
- Take right before going to bed 1
This is not a flexible recommendation—it's a mandatory administration instruction designed to prevent serious safety issues.
Why Nighttime-Only Use Is Critical
CNS Depressant Effects and Next-Day Impairment
Lemborexant has a half-life of 17-19 hours 2, meaning significant drug levels persist well into the next day. The FDA warns that:
- Your ability to drive safely and think clearly may be decreased the morning after taking DAYVIGO
- You may have sleepiness during the day
- The risk of daytime impairment increases if taken with less than a full 7-hour sleep period remaining 1
Driving Performance Data
Controlled studies demonstrated that while 5 mg and 10 mg doses didn't cause statistically significant impairment in next-morning driving performance approximately 9 hours after dosing, driving ability was impaired in some subjects taking 10 mg 1. This individual variation in sensitivity makes the 7-hour sleep requirement even more critical.
Common Adverse Effects
The most common side effect is somnolence, occurring in approximately 10% of patients at the 10 mg dose 2, 3. Treatment-emergent adverse events and somnolence were statistically significantly higher with lemborexant compared to placebo (RR = 1.94 and RR = 4.95, respectively) 3.
Clinical Context: Insomnia Treatment Indication
Lemborexant is FDA-approved specifically for adults who have trouble falling or staying asleep (insomnia) 1. The drug works by blocking orexin receptors that promote wakefulness—this mechanism inherently makes it inappropriate for daytime use when wakefulness is desired.
Clinical trials demonstrated efficacy for:
- Sleep onset latency (reduced by 9-13 minutes vs placebo)
- Wake after sleep onset (reduced by 19-22 minutes vs placebo)
- Sleep efficiency (improved by 6-7% vs placebo) 3
These benefits are specifically designed to facilitate nighttime sleep, not daytime sedation.
Critical Safety Warnings
Beyond daytime impairment, nighttime-only use helps minimize risks of:
- Complex sleep behaviors (sleep-walking, sleep-driving, eating while not fully awake)
- Sleep paralysis and hypnagogic/hypnopompic hallucinations
- Cataplexy-like symptoms
- Falls risk from increased drowsiness 1, 2
Common Pitfall to Avoid
Do not use lemborexant for daytime napping or shift work sleep disorder—it is not indicated or studied for these purposes. The drug's long half-life and potential for next-day impairment make it unsuitable for any sleep period shorter than 7 hours or for sleep periods that don't align with nighttime.
If a patient reports needing sleep assistance during daytime hours, this represents either:
- Misuse of the medication requiring immediate counseling
- An underlying sleep disorder (like shift work disorder or circadian rhythm disorder) requiring different therapeutic approaches